Viking Therapeutics, Inc. (VKTX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in San Diego, CA, United States. Der aktuelle CEO ist Brian Lian.
VKTX hat IPO-Datum 2015-04-28, 45 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $4.1B.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for metabolic and endocrine disorders. The company's lead candidate, VK2809, is an orally available thyroid hormone receptor beta agonist currently in Phase IIb trials for non-alcoholic steatohepatitis and fatty liver disease. Viking's pipeline also includes VK5211, a selective androgen receptor modulator in Phase II development for hip fracture recovery; VK0612, a Phase IIb-ready candidate for type 2 diabetes; and VK0214, another thyroid hormone receptor beta agonist for X-linked adrenoleukodystrophy. Founded in 2012, the company focuses on addressing significant unmet medical needs in metabolic and endocrine disease treatment.
